349 related articles for article (PubMed ID: 30309818)
1. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
[TBL] [Abstract][Full Text] [Related]
2. An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese.
Wang Y; Yu Y; Ye R; Zhang D; Li Q; An D; Fang L; Lin Y; Hou Y; Xu A; Fu Y; Lu W; Chen X; Chen M; Zhang M; Jiang H; Zhang C; Dong P; Li C; Chen J; Yang G; Liu C; Cai Z; Zhou F; Wu S
Oncotarget; 2016 Jan; 7(3):2754-64. PubMed ID: 26700620
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation.
Reinert T; Borre M; Christiansen A; Hermann GG; Ørntoft TF; Dyrskjøt L
PLoS One; 2012; 7(10):e46297. PubMed ID: 23056278
[TBL] [Abstract][Full Text] [Related]
4. Identification of Cancer-Specific Methylation of Gene Combination for the Diagnosis of Bladder Cancer.
Zhang N; Chen S; Wu L; Wu Y; Jiang G; Shao J; Chen L; Sun J; Na R; Wang X; Xu J
J Cancer; 2019; 10(26):6761-6766. PubMed ID: 31777606
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria.
van Kessel KE; Van Neste L; Lurkin I; Zwarthoff EC; Van Criekinge W
J Urol; 2016 Mar; 195(3):601-7. PubMed ID: 26327355
[TBL] [Abstract][Full Text] [Related]
6. A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines.
de Jong JJ; Pijpers OM; van Kessel KEM; Boormans JL; Van Criekinge W; Zwarthoff EC; Lotan Y
Eur Urol Oncol; 2023 Apr; 6(2):183-189. PubMed ID: 36089502
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
8. Improved urine DNA methylation panel for early bladder cancer detection.
Fang Q; Zhang X; Nie Q; Hu J; Zhou S; Wang C
BMC Cancer; 2022 Mar; 22(1):237. PubMed ID: 35241014
[TBL] [Abstract][Full Text] [Related]
9. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
[TBL] [Abstract][Full Text] [Related]
10. A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.
van Kessel KEM; de Jong JJ; Ziel-van der Made ACJ; Roshani H; Haensel SM; Wolterbeek JH; Boevé ER; Oomens EHGM; van Casteren NJ; Krispin M; Boormans JL; Steyerberg EW; van Criekinge W; Zwarthoff EC
J Urol; 2020 Jul; 204(1):50-57. PubMed ID: 31985322
[TBL] [Abstract][Full Text] [Related]
11. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
[TBL] [Abstract][Full Text] [Related]
12. BladMetrix: a novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients.
Pharo HD; Jeanmougin M; Ager-Wick E; Vedeld HM; Sørbø AK; Dahl C; Larsen LK; Honne H; Brandt-Winge S; Five MB; Monteiro-Reis S; Henrique R; Jeronimo C; Steven K; Wahlqvist R; Guldberg P; Lind GE
Clin Epigenetics; 2022 Sep; 14(1):115. PubMed ID: 36115961
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.
Renard I; Joniau S; van Cleynenbreugel B; Collette C; Naômé C; Vlassenbroeck I; Nicolas H; de Leval J; Straub J; Van Criekinge W; Hamida W; Hellel M; Thomas A; de Leval L; Bierau K; Waltregny D
Eur Urol; 2010 Jul; 58(1):96-104. PubMed ID: 19674832
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.
Bangma CH; Loeb S; Busstra M; Zhu X; El Bouazzaoui S; Refos J; Van Der Keur KA; Tjin S; Franken CG; van Leenders GJ; Zwarthoff EC; Roobol MJ
Eur Urol; 2013 Jul; 64(1):41-7. PubMed ID: 23478169
[TBL] [Abstract][Full Text] [Related]
15. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
16. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.
Chen X; Zhang J; Ruan W; Huang M; Wang C; Wang H; Jiang Z; Wang S; Liu Z; Liu C; Tan W; Yang J; Chen J; Chen Z; Li X; Zhang X; Xu P; Chen L; Xie R; Zhou Q; Xu S; Irwin DL; Fan JB; Huang J; Lin T
J Clin Invest; 2020 Dec; 130(12):6278-6289. PubMed ID: 32817589
[TBL] [Abstract][Full Text] [Related]
17. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
Hermanns T; Savio AJ; Olkhov-Mitsel E; Mari A; Wettstein MS; Saba K; Bhindi B; Kuk C; Poyet C; Wild PJ; Noon A; Bashir S; Juvet T; Rendon RA; Waltregny D; van der Kwast T; Finelli A; Kulkarni GS; Fleshner NE; Lo K; Bapat B; Zlotta AR
Urol Oncol; 2020 Jun; 38(6):603.e1-603.e7. PubMed ID: 32081560
[TBL] [Abstract][Full Text] [Related]
18. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection.
Urquidi V; Goodison S; Kim J; Chang M; Dai Y; Rosser CJ
Urology; 2012 May; 79(5):1185.e1-6. PubMed ID: 22386755
[TBL] [Abstract][Full Text] [Related]
20. The use of molecular analyses in voided urine for the assessment of patients with hematuria.
Beukers W; Kandimalla R; van Houwelingen D; Kovacic H; Chin JF; Lingsma HF; Dyrskjot L; Zwarthoff EC
PLoS One; 2013; 8(10):e77657. PubMed ID: 24143252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]